Latent KSHV infection increases the vascular permeability of human endothelial cells

Blood

Volumn 118, Issue 19, 2011, Pages 5344-5354

  Guilluy, Christophe ^a   Zhang, Zhigang ^a,b   Bhende, Prasanna M ^a,b   Sharek, Lisa ^a   Wang, Ling ^a,b   Burridge, Keith ^a,b   Damania, Blossom ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CADHERIN; P21 ACTIVATED KINASE 1; RAC1 PROTEIN; REACTIVE OXYGEN METABOLITE;

ARTICLE; BLOOD VESSEL PERMEABILITY; CELL JUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVITY; HERPES VIRUS INFECTION; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; KAPOSI SARCOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 81155123214     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-341552     Document Type: Article

References (50)

1. Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature. 2005;437(7058):497-504. (Pubitemid 41613541)
2. May C, Doody JF, Abdullah R, et al. Identification of a transiently exposed VE-cadherin epitope that allows for specific targeting of an antibody to the tumor neovasculature. Blood. 2005;105(11):4337-4344. (Pubitemid 40723657)
3. Fukuhara S, Sakurai A, Sano H, et al. Cyclic AMP potentiates vascular endothelial cadherin-mediated cell-cell contact to enhance endothelial barrier function through an Epac-Rap1 signaling pathway. Mol Cell Biol. 2005;25(1):136-146. (Pubitemid 40039806)
4. Weis S, Cui J, Barnes L, Cheresh D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol. 2004;167(2):223-229. (Pubitemid 39435066)
5. Corada M, Mariotti M, Thurston G, et al. Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc Natl Acad Sci U S A. 1999;96(17):9815-9820. (Pubitemid 29398815)
6. Gavard J, Gutkind JS. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol. 2006;8(11):1223-1234. (Pubitemid 44660587)
7. Garrett TA, Van Buul JD, Burridge K. VEGF-induced Rac1 activation in endothelial cells is regulated by the guanine nucleotide exchange factor Vav2. Exp Cell Res. 2007;313(15):3285-3297. (Pubitemid 47284065)
8. Stockton RA, Schaefer E, Schwartz MA. p21-activated kinase regulates endothelial permeability through modulation of contractility. J Biol Chem. 2004;279(45):46621-46630. (Pubitemid 39518307)
9. Monaghan-Benson E, Burridge K. The regulation of vascular endothelial growth factor-induced microvascular permeability requires Rac and reactive oxygen species. J Biol Chem. 2009;284(38):25602-25611.
10. Monaghan-Benson E, Hartmann J, Vendrov AE, et al. The role of vascular endothelial growth factor-induced activation of NADPH oxidase in choroidal endothelial cells and choroidal neovascularization. Am J Pathol. 2010;177(4):2091-2102.
11. Boshoff C, Schulz TF, Kennedy MM, et al. Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat Med. 1995;1(12):1274- 1278.
12. Humphrey RW, Davis DA, Newcomb FM, Yarchoan R. Human herpesvirus 8 (HHV-8) in the pathogenesis of Kaposi's sarcoma and other diseases. Leuk Lymphoma. 1998;28(3-4):255-264. (Pubitemid 28105032)
13. Dupin N, Grandadam M, Calvez V, et al. Herpesvirus-like DNA sequences in patients with Mediterranean Kaposi's sarcoma. Lancet. 1995;345(8952):761-762.
14. Bernstein WB, Little RF, Wilson WH, Yarchoan R. Acquired immunodeficiency syndrome-related malignancies in the era of highly active antiretroviral therapy. Int J Hematol. 2006;84(1):3-11. (Pubitemid 44756769)
15. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995;332(18):1186-1191.
16. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood. 1995;86(4):1276-1280.
17. Dupin N, Fisher C, Kellam P, et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A. 1999;96(8):4546-4551. (Pubitemid 29190373)
18. Boshoff C, Endo Y, Collins PD, et al. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science. 1997;278(5336):290-294. (Pubitemid 27450876)
19. Aoki Y, Jaffe ES, Chang Y, et al. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood. 1999;93(12):4034-4043. (Pubitemid 29279245)
20. Sakakibara S, Tosato G. Regulation of angiogenesis in malignancies associated with Epstein-Barr virus and Kaposi's sarcoma-associated herpes virus. Future Microbiol. 2009;4(7):903-917.
21. Yao L, Salvucci O, Cardones AR, et al. Selective expression of stromal-derived factor-1 in the capillary vascular endothelium plays a role in Kaposi sarcoma pathogenesis. Blood. 2003;102(12):3900-3905. (Pubitemid 37486968)
22. Samaniego F, Markham PD, Gendelman R, et al. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. Am J Pathol. 1998;152(6):1433-1443. (Pubitemid 28275002)
23. Blankaert D, Simonart T, Van Vooren JP, et al. Constitutive release of metalloproteinase-9 (92-kd type IV collagenase) by Kaposi's sarcoma cells. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(3):203-209.
24. Bais C, Van Geelen A, Eroles P, et al. Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/KDR. Cancer Cell. 2003;3(2):131-143. (Pubitemid 37443386)
25. Montaner S, Sodhi A, Servitja JM, et al. The small GTPase Rac1 links the Kaposi sarcoma-associated herpesvirus vGPCR to cytokine secretion and paracrine neoplasia. Blood. 2004;104(9):2903-2911. (Pubitemid 39434978)
26. Wang L, Dittmer DP, Tomlinson CC, Fakhari FD, Damania B. Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus. Cancer Res. 2006;66(7):3658-3666.
27. Wen KW, Damania B. Hsp90 and Hsp40/Erdj3 are required for the expression and anti-apoptotic function of KSHV K1. Oncogene. 2010;29(24):3532-3544.
28. Chandriani S, Ganem D. Array-based transcript profiling and limiting-dilution reverse transcription-PCR analysis identify additional latent genes in Kaposi's sarcoma-associated herpesvirus. J Virol. 2010;84(11):5565- 5573.
29. Wang L, Damania B. Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells. Cancer Res. 2008;68(12):4640-4648.
30. Allingham MJ, van Buul JD, Burridge K. ICAM-1-mediated, Src- and Pyk2-dependent vascular endothelial cadherin tyrosine phosphorylation is required for leukocyte transendothelial migration. J Immunol. 2007;179(6):4053-4064.
31. del Pozo MA, Price LS, Alderson NB, Ren XD, Schwartz MA. Adhesion to the extracellular matrix regulates the coupling of the small GTPase Rac to its effector PAK. EMBO J. 2000;19(9):2008-2014. (Pubitemid 30237576)
32. Knaus UG, Morris S, Dong HJ, Chernoff J, Bokoch GM. Regulation of human leukocyte p21-activated kinases through G protein-coupled receptors. Science. 1995;269(5221):221-223.
33. Vieira J, O'Hearn PM. Use of the red fluorescent protein as a marker of Kaposi's sarcoma-associated herpesvirus lytic gene expression. Virology. 2004;325(2):225-240. (Pubitemid 38902789)
34. Sivakumar R, Sharma-Walia N, Raghu H, et al. Kaposi's sarcoma-associated herpesvirus induces sustained levels of vascular endothelial growth factors A and C early during in vitro infection of human microvascular dermal endothelial cells: biological implications. J Virol. 2008;82(4):1759-1776. (Pubitemid 351206926)
35. Servitja JM, Marinissen MJ, Sodhi A, Bustelo XR, Gutkind JS. Rac1 function is required for Src-induced transformation. Evidence of a role for Tiam1 and Vav2 in Rac activation by Src. J Biol Chem. 2003;278(36):34339-34346. (Pubitemid 37553278)
36. Manser E, Leung T, Salihuddin H, Zhao ZS, Lim L. A brain serine/threonine protein kinase activated by Cdc42 and Rac1. Nature. 1994;367(6458):40-46. (Pubitemid 24038530)
37. Sells MA, Knaus UG, Bagrodia S, Ambrose DM, Bokoch GM, Chernoff J. Human p21-activated kinase (Pak1) regulates actin organization in mammalian cells. Curr Biol. 1997;7(3):202-210. (Pubitemid 27164726)
38. van Wetering S, van Buul JD, Quik S, et al. Reactive oxygen species mediate Rac-induced loss of cell-cell adhesion in primary human endothelial cells. J Cell Sci. 2002;115(Pt 9):1837-1846. (Pubitemid 34567245)
39. Braga VM, Machesky LM, Hall A, Hotchin NA. The small GTPases Rho and Rac are required for the establishment of cadherin-dependent cell-cell contacts. J Cell Biol. 1997;137(6):1421-1431. (Pubitemid 27265952)
40. Potter MD, Barbero S, Cheresh DA. Tyrosine phosphorylation of VE-cadherin prevents binding of p120- and beta-catenin and maintains the cellular mesenchymal state. J Biol Chem. 2005;280(36):31906-31912. (Pubitemid 41291941)
41. Friedl P, Gilmour D. Collective cell migration in morphogenesis, regeneration and cancer. Nat Rev Mol Cell Biol. 2009;10(7):445-457.
42. Wang L, Wakisaka N, Tomlinson CC, et al. The Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) K1 protein induces expression of angiogenic and invasion factors. Cancer Res. 2004;64(8):2774-2781. (Pubitemid 38500615)
43. An FQ, Folarin HM, Compitello N, et al. Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo. J Virol. 2006;80(10):4833-4846.
44. Qian LW, Greene W, Ye F, Gao SJ. Kaposi's sarcoma-associated herpesvirus disrupts adherens junctions and increases endothelial permeability by inducing degradation of VE-cadherin. J Virol. 2008;82(23):11902-11912.
45. Mansouri M, Rose PP, Moses AV, Fruh K. Remodeling of endothelial adherens junctions by Kaposi's sarcoma-associated herpesvirus. J Virol. 2008;82(19):9615-9628.
46. Dwyer J, Le Guelte A, Galan Moya EM, et al. Remodeling of VE-cadherin junctions by the human herpes virus 8 G-protein coupled receptor. Oncogene. 2011;30(2):190-200.
47. Lassègue B, Griendling KK. NADPH oxidases: functions and pathologies in the vasculature. Arterioscler Thromb Vasc Biol. 2010;30(4):653-661.
48. Ma Q, Cavallin LE, Yan B, et al. Antitumorigenesis of antioxidants in a transgenic Rac1 model of Kaposi's sarcoma. Proc Natl Acad Sci U S A. 2009;106(21):8683-8688.
49. Montaner S, Sodhi A, Molinolo A, et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell. 2003;3(1):23-36. (Pubitemid 37443889)
50. Mitsuyasu RT. Update on the pathogenesis and treatment of Kaposi sarcoma. Curr Opin Oncol. 2000;12(2):174-180. (Pubitemid 32043960)